These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 30963549)

  • 21. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries.
    Walker RI
    Vaccine; 2005 May; 23(26):3369-85. PubMed ID: 15837361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.
    Korkmaz E; Balmert SC; Carey CD; Erdos G; Falo LD
    Expert Opin Drug Deliv; 2021 Feb; 18(2):151-167. PubMed ID: 32924651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nasal vaccine innovation.
    Jabbal-Gill I
    J Drug Target; 2010 Dec; 18(10):771-86. PubMed ID: 21047271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with inactivated, virosomal influenza vaccine.
    de Bruijn IA; Nauta J; Cramer WC; Gerez L; Palache AM
    Vaccine; 2005 Jul; 23 Suppl 1():S39-49. PubMed ID: 16005120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.
    Girard MP; Katz JM; Pervikov Y; Hombach J; Tam JS
    Vaccine; 2011 Oct; 29(44):7579-86. PubMed ID: 21856358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses.
    Abente EJ; Rajao DS; Santos J; Kaplan BS; Nicholson TL; Brockmeier SL; Gauger PC; Perez DR; Vincent AL
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delivery technologies for human vaccines.
    Moingeon P; de Taisne C; Almond J
    Br Med Bull; 2002; 62(1):29-44. PubMed ID: 12176848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bridging nanoplatform and vaccine delivery, a landscape of strategy to enhance nasal immunity.
    Teng Z; Meng LY; Yang JK; He Z; Chen XG; Liu Y
    J Control Release; 2022 Nov; 351():456-475. PubMed ID: 36174803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fish vaccine antigens produced or delivered by recombinant DNA technologies.
    Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G
    Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.
    Cox RJ; Brokstad KA; Ogra P
    Scand J Immunol; 2004 Jan; 59(1):1-15. PubMed ID: 14723616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal formulations: promising strategy to deliver vaccines.
    Riese P; Sakthivel P; Trittel S; Guzmán CA
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1619-34. PubMed ID: 24962722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: a cluster randomized trial.
    Kwong JC; Pereira JA; Quach S; Pellizzari R; Dusome E; Russell ML; Hamid JS; Feinberg Y; Winter AL; Gubbay JB; Sirtonski B; Moher D; Sider D; Finkelstein M; Loeb M;
    Vaccine; 2015 Jan; 33(4):535-41. PubMed ID: 25488331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The state-of-the-art of approved and under-development cholera vaccines.
    Pastor M; Pedraz JL; Esquisabel A
    Vaccine; 2013 Aug; 31(38):4069-78. PubMed ID: 23845813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rhabdovirus-based vaccine platforms against henipaviruses.
    Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
    J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody response and maternal immunity upon boosting PRRSV-immune sows with experimental farm-specific and commercial PRRSV vaccines.
    Geldhof MF; Van Breedam W; De Jong E; Lopez Rodriguez A; Karniychuk UU; Vanhee M; Van Doorsselaere J; Maes D; Nauwynck HJ
    Vet Microbiol; 2013 Dec; 167(3-4):260-71. PubMed ID: 24041768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccines for preventing influenza in healthy children.
    Jefferson T; Rivetti A; Di Pietrantonj C; Demicheli V
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD004879. PubMed ID: 29388195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of reverse vaccinology approaches for the development of vaccines against ticks and tick borne diseases.
    Lew-Tabor AE; Rodriguez Valle M
    Ticks Tick Borne Dis; 2016 Jun; 7(4):573-85. PubMed ID: 26723274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Chicken Interferon Gamma on Newcastle Disease Virus Vaccine Immunogenicity.
    Cardenas-Garcia S; Dunwoody RP; Marcano V; Diel DG; Williams RJ; Gogal RM; Brown CC; Miller PJ; Afonso CL
    PLoS One; 2016; 11(7):e0159153. PubMed ID: 27409587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.